Award
National Heart, Lung, and Blood Institute 1R41HL180136-01
Repurposing Pyrvinium as an Inhalation Therapy for Idiopathic Pulmonary Fibrosis
Recipient
Not specified
Award Amount
$309,418.00
Ceiling
$309,418.00
Awarded
September 17, 2025
Identifier
1R41HL180136-01
Award for research and development of inhaled Pyrvinium therapy for idiopathic pulmonary fibrosis, including preclinical studies to support clinical trial development.
Description
The project involves investigating the safety and efficacy of inhaled Pyrvinium for IPF, including in vivo mouse models and ex vivo human lung tissue studies, aiming to support further development towards clinical trials.